Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin.
Warfarin is, among drugs, considered to have a narrow therapeutic index for which individual bioequivalence has been suggested. To establish the propriety of "switching," an individual bioequivalence study involving a replicate-design study and three "switchings" in healthy subjects was undertaken using the U.S.-brand warfarin sodium tablet and a generic product. A randomized, single-center, open-label, single-dose, four-way crossover replicate bioequivalence study was performed in 24 healthy male volunteers in which each subject received the same 5 mg warfarin test and reference tablets twice on different occasions under fasting conditions. Concentrations of warfarin in plasma were measured by a validated specific HPLC method. The individual pharmacokinetic parameters obtained with test and reference products were compared using pooled data and Liu's method. Bioequivalence was shown with both average and individual bioequivalence methods. The individual bioequivalence assessment did not show a subject-by-formulation interaction, nor did it add value to the bioequivalence assessment of warfarin.
Taro Research Institute, Ltd., Israel.
A
A
Yacobi
E
E
Masson
D
D
Moros
D
D
Ganes
C
C
Lapointe
Z
Z
Abolfathi
M
M
LeBel
Y
Y
Golander
D
D
Doepner
T
T
Blumberg
Y
Y
Cohen
B
B
Levitt
D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000493:pharmacokinetics*
D000925:Anticoagulants; D014859:Warfarin